Motley Fool Money

CRISPR, Gene Therapies, and Cure Pricing Conundrums

Sep 17, 2022

Karl Thiel, a Motley Fool advisor and CRISPR expert, dives into the fascinating world of gene editing. He explains how CRISPR acts like molecular scissors with profound implications for health and agriculture. The discussion highlights the ethical dilemmas and pricing challenges faced by gene therapies. Thiel also explores how investors can navigate this complex landscape, offering insights into promising biotech metrics. With potential applications ranging from curing diseases to developing drought-resistant crops, the future of CRISPR is both exciting and controversial.

24:07

Creator website

Episode guests

Karl Thiel

AI Chapters

Episode notes

Intro

2min

The CRISPR Revolution: Innovation and Ethics

10min

The Price of Cures: Navigating Gene Therapy Economics

8min

Insights into Biotech Ownership and CRISPR Therapeutics Challenges

2min

Exploring the Future Potential of CRISPR Technology

2min

Genetically edited humans are already here. Gene editing has massive implications for treating chronic illnesses and even the food we eat. So what does this mean for your investments and, y'know, possibly humanity? Ricky Mulvey talks with Motley Fool Advisor Karl Thiel about: - How CRISPR works - Some of the possibilities for CRISPR, from sickle cell cures to drought-resistant crops - How investors can approach investing in gene therapies - Biotech metrics to watch.

Companies mentioned: BLUE, CRSP, GILD, EDIT, VRTX, NTLA

Host: Ricky Mulvey Guest: Karl Theil Engineers: Tim Sparks, Dan Boyd

Learn more about your ad choices. Visit megaphone.fm/adchoices

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.